FL
FLGT.O
—
NASDAQ
Health Care Providers & Services
Flgt.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-28,2 %
ROE
-5,4 %
Net margin
-18,8 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$19,63
Open
$19,58
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Fulgent Genetics Inc. operates as a clinical laboratory providing diagnostic testing services, including next-generation sequencing and immunohistochemistry, relying on key suppliers such as Illumina Inc. for sequencing equipment and reagents.
Business. Fulgent Genetics Inc. operates as a clinical laboratory providing diagnostic testing services, including next-generation sequencing and immunohistochemistry, relying on key suppliers such as Illumina Inc. for sequencing equipment and reagents.
Classification85 %
SectorHealth Care
Industry groupHealth Care Providers & Services
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Dimensional Fund Advisors, L.P.
largest disclosed fund holder
Profitability→
-5,4 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to FLGT.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Fulgent Genetics Inc. operates as a clinical laboratory providing diagnostic testing services, including next-generation sequencing and immunohistochemistry, relying on key suppliers such as Illumina Inc. for sequencing equipment and reagents.
Classification85 %
SectorHealth Care
Industry groupHealth Care Providers & Services
AI synthesis
GENERATEDFulgent Genetics maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet shows total assets of $1.21 billion against total liabilities of $106.8 million, leaving total equity at $1.11 billion. Cash and equivalents stand at $50.2 million, which is modest relative to the asset base but sufficient given the absence of debt obligations. Operating cash flow is negative at -$101.6 million, indicating that the company is consuming cash to fund operations, while capital expenditures are recorded at $22.6 million. The liquidity risk is assessed as low, and no immediate filing-based liquidity flags were detected.
Profitability metrics reflect the company's growth-stage or investment-heavy phase, with a net loss of $60.5 million on revenue of $322.7 million. The return on equity is -5.44% and return on assets is -4.99%, indicating that the company is not yet generating positive returns on its capital base. Gross profit is $130.9 million, yielding a gross margin of approximately 40.6%, but operating income is negative at -$91.1 million, highlighting significant operating expenses that exceed gross margins. Without cohort median data for direct comparison, these negative returns are typical for specialized diagnostic firms investing heavily in technology and regulatory compliance.
Key takeaways
- Fulgent Genetics operates with zero debt, maintaining a strong equity base of $1.11 billion but facing negative operating cash flow of -$101.6 million.
- The company relies exclusively on Illumina for next-generation sequencing equipment and reagents, creating a single-point-of-failure risk in its supply chain.
- Net loss of $60.5 million on $322.7 million in revenue results in negative returns on equity (-5.44%) and assets (-4.99%).
- Low liquidity and dilution risks are assessed, with no immediate filing-based flags detected.
- The company operates through multiple subsidiaries, including Fulgent Pharma Holdings and Fulgent Australia, indicating a diversified operational structure.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$17,61
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$1.11B
Net cashⓘ
$50.2M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
-5.0%
ROEⓘ
-5.4%
Cash conversionⓘ
168.0%
CapEx / revenueⓘ
7.0%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships10 disclosed relationships · 2 types · extracted from filings & disclosures
Suppliers3
Abbott LaboratoriesABT.OSupplier100%Source ↗
Illumina IncILMN.OSupplier100%Source ↗
Roche Holding AGROG.TOSupplier100%Source ↗
Subsidiaries7
EX21:66a8f0af2571EX21:66a8f0af2571Subsidiarie97%
EX21:70c94ef16e64EX21:70c94ef16e64Subsidiarie97%
EX21:875f19e5a55aEX21:875f19e5a55aSubsidiarie97%
EX21:8bdb3aef8ab1EX21:8bdb3aef8ab1Subsidiarie97%
EX21:ae206322532fEX21:ae206322532fSubsidiarie97%
EX21:c5427d307f7dEX21:c5427d307f7dSubsidiarie97%
EX21:fded0278d4e7EX21:fded0278d4e7Subsidiarie97%
Supply chain
Vendors → FLGT ↔ Partners → Customers · click any node to drill
3 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution1 analysts
Strong buy0
Buy0
Hold1
Sell0
Strong sell0
12-month price target$15,00 · Median $15,00
Low $15,00High $15,00
Operating income · consensus-102,0M USD
EPS surprise
+127,1 %
reported vs consensus · beat
Revenue surprise
−8,3 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$15,00
Mean$15,00
Median$15,00
High$15,00
Spot$17,61
−14.8 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-28,2 %Bottom quartile
Net Margin-18,8 %Bottom quartile
ROE-5,4 %Below median
Capex / Rev7,0 %Best in class
D/E0,00Above median
Cash Conv1,68Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 741 574 sh1 grants2 insiders
- Director · Stock Option (Right to Buy) → Common StockAcquired 8 426 @ $16,19grant · 2026-05-14
- Director, Chief Executive Officer, 10% owner · Forward sale contract (obligation to sell) → Common StockDisposed 750 000other · 2026-03-09
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
Source documents
- Fulgent Genetics, Inc. Market data — financials · 2026-07-29
- reconciler_enqueue (reconciler) on FLGT.O · 2026-07-29
- FLGT.O HA canonical relationships · 2026-07-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$11M
- Institutional Investor · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2024-06-300,00 %$77M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2025-12-310,00 %$33M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$8M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$3M
- Funds · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Ming HsiehChairman of the Board, Chief Executive Officer
Insider activity
Net selling0 buys · 4 sellsnet -$106K7 insiders · last 365d
- President and COO · Common StockOther 4 361 @ $19,67$86K · 2026-07-26
- CFO and Treasurer · Common StockOther 2 747 @ $19,67$54K · 2026-07-26
- Chief Scientific Officer · Common StockOther 1 645 @ $19,67$32K · 2026-07-26
- Chief Scientific Officer · Common StockSold 1 688 @ $17,89$30K · 2026-06-02
- President and COO · Common StockSold 2 146 @ $17,89$38K · 2026-06-02
- CFO and Treasurer · Common StockOther 2 087 @ $18,09$38K · 2026-06-01
- Director, Chief Executive Officer, 10% owner · Common StockOther 4 392 @ $18,09$79K · 2026-06-01
- Chief Scientific Officer · Common StockSold 945 @ $17,60$17K · 2026-05-27
- President and COO · Common StockSold 1 201 @ $17,60$21K · 2026-05-27
- CFO and Treasurer · Common StockOther 1 168 @ $17,67$21K · 2026-05-26
- Director, Chief Executive Officer, 10% owner · Common StockOther 2 949 @ $17,67$52K · 2026-05-26
- Director · Common StockOther 5 558 · 2026-05-14
- Director · Common StockOther 11 117 · 2026-05-14
- Director · Common StockOther 11 117 · 2026-05-14
- Chief Scientific Officer · Common StockOther 1 645 @ $16,31$27K · 2026-04-26
- CFO and Treasurer · Common StockOther 2 747 @ $16,31$45K · 2026-04-26
- President and COO · Common StockOther 4 361 @ $16,31$71K · 2026-04-26
- Chief Scientific Officer · Common StockOther 6 410 @ $15,33$98K · 2026-03-01
- Director, Chief Executive Officer, 10% owner · Common StockOther 17 566 @ $15,33$269K · 2026-03-01
- President and COO · Common StockOther 8 147 @ $15,33$125K · 2026-03-01
- CFO and Treasurer · Common StockOther 1 133 @ $15,33$17K · 2026-03-01
- CFO and Treasurer · Common StockOther 8 347 @ $15,33$128K · 2026-03-01
- Chief Scientific Officer · Common StockOther 1 018 @ $15,33$16K · 2026-03-01
- President and COO · Common StockOther 1 079 @ $15,33$17K · 2026-03-01
- President and COO · Common StockOther 1 140 @ $24,76$28K · 2026-02-26
Short positioning
2.8Mshares short+4.8% vs prior
11.43days to cover
69.0%short of daily vol
43fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
FLGT.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorSuppliersSubsidiaries
Evidence & claims
From filings & derived data- Cash & equivalents (annual): USD 50.19MUnknown
- Shares outstanding (annual): 31.08MUnknown
- Operating cash flow (annual): USD -101.64MUnknown
- Total assets (annual): USD 1.21BUnknown
- R&D expense (annual): USD 53.91MUnknown
- Current liabilities (annual): USD 84.97MUnknown
- Total liabilities (annual): USD 106.81MUnknown
- Operating income (annual): USD -91.1MUnknown
- Capex (annual): USD 22.57MUnknown
- Current assets (annual): USD 550.49MUnknown
- Revenue (annual): USD 322.67MUnknown
- Shareholders' equity (annual): USD 1.11BUnknown
- Gross profit (annual): USD 130.88MUnknown
- Cost of revenue (annual): USD 191.8MUnknown
- Pre-tax income (annual): USD -70.03MUnknown
- Net income (annual): USD -60.51MUnknown
- Total operating expenses (annual): USD 221.97MUnknown
- Operating income (annual): USD -73.92MUnknown
- Shares outstanding (annual): 30.84MUnknown
- Cash & equivalents (annual): USD 55.14MUnknown
- Pre-tax income (annual): USD -51.96MUnknown
- Current assets (annual): USD 353.57MUnknown
- Operating cash flow (annual): USD 21.06MUnknown
- Capex (annual): USD 40.31MUnknown
Showing 24 of 34 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-30 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-07-30EVENTQ2 2026 earnings (expected) estimated date
2026-07-26INSIDERXie Jian transacted 4.4k sh — President and COO ~$86k
2026-07-26INSIDERGao Hanlin transacted 1.6k sh — Chief Scientific Officer ~$32k
2026-07-26INSIDERKim Paul transacted 2.7k sh — CFO and Treasurer ~$54k
2026-06-02 00:00 UTCINSIDER4 insider transactions — 2026-06 · net sell $186k
2026-06-02 00:00 UTCINSIDER4 insider transactions — 2026-06 · net sell $186k
2026-06-02INSIDERXie Jian sold 2.1k sh — President and COO ~$38k
2026-06-02INSIDERGao Hanlin sold 1.7k sh — Chief Scientific Officer ~$30k
2026-06-01INSIDERHsieh Ming transacted 4.4k sh — Director, Chief Executive Officer, 10% owner ~$79k
2026-06-01INSIDERKim Paul transacted 2.1k sh — CFO and Treasurer ~$38k
2026-05-27 00:00 UTCINSIDER8 insider transactions — 2026-05 · net sell $111k 1 derivative
2026-05-27 00:00 UTCINSIDER8 insider transactions — 2026-05 · net sell $111k 1 derivative
2026-05-27INSIDERGao Hanlin sold 945 sh — Chief Scientific Officer ~$17k
2026-05-27INSIDERXie Jian sold 1.2k sh — President and COO ~$21k
2026-05-26INSIDERHsieh Ming transacted 2.9k sh — Director, Chief Executive Officer, 10% owner ~$52k
2026-05-26INSIDERKim Paul transacted 1.2k sh — CFO and Treasurer ~$21k
2026-05-14INSIDERGROVES REGINA E transacted 11.1k sh — Director
2026-05-14INSIDERNohaile Michael transacted 5.6k sh — Director
2026-05-14INSIDERDong Linda transacted 11.1k sh — Director
2026-05-14INSIDERNohaile Michael acquired 8.4k sh Stock Option (Right to Buy) — Director
2026-04-26 00:00 UTCINSIDER3 insider transactions — 2026-04 · net sell $143k
2026-04-26 00:00 UTCINSIDER3 insider transactions — 2026-04 · net sell $143k
2026-04-26INSIDERGao Hanlin transacted 1.6k sh — Chief Scientific Officer ~$27k
2026-04-26INSIDERXie Jian transacted 4.4k sh — President and COO ~$71k
2026-04-26INSIDERKim Paul transacted 2.7k sh — CFO and Treasurer ~$45k
2026-03-09 00:00 UTCINSIDER8 insider transactions — 2026-03 · net sell $670k 1 derivative
2026-03-09 00:00 UTCINSIDER8 insider transactions — 2026-03 · net sell $670k 1 derivative
2026-03-09INSIDERHsieh Ming disposed of 750.0k sh Forward sale contract (obligation to sell) — Director, Chief Executive Officer, 10% owner
2026-03-01INSIDERKim Paul transacted 8.3k sh — CFO and Treasurer ~$128k
2026-03-01INSIDERXie Jian transacted 1.1k sh — President and COO ~$17k
2026-03-01INSIDERGao Hanlin transacted 1.0k sh — Chief Scientific Officer ~$16k
Showing the 40 most recent of 50 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage